英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Kriya查看　Kriya　在百度字典中的解释百度英翻中〔查看〕
Kriya查看　Kriya　在Google字典中的解释Google英翻中〔查看〕
Kriya查看　Kriya　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Kriya Therapeutics: Gene Therapy. Redefined.
    Kriya is targeting diseases that impact millions of people worldwide and represent areas of high unmet need We target validated biological pathways with innovative gene therapy approaches that have the potential to deliver transformative benefits
  • Pipeline - Kriya Therapeutics
    Kriya is developing a portfolio of one-time gene therapies to address chronic diseases Our current pipeline includes three main therapeutic areas: Therapeutic Area
  • Neurology: Gene Therapy for Trigeminal Neuralgia - Kriya Therapeutics
    Kriya’s adeno-associated virus (AAV) gene therapy is designed to durably express an engineered ion channel focally within the trigeminal nerve, which may provide targeted pain relief
  • Kriya Announces Gene Therapy Program for Thyroid Eye Disease
    Kriya is developing KRIYA-586, a one-time, adeno-associated virus (AAV) gene therapy that drives durable expression of a monoclonal antibody that blocks IGF-1 receptors
  • Kriya Presents Data at the 2025 Association for Research in Vision and . . .
    Kriya is developing KRIYA-825, a potential one-time gene therapy for Geographic Atrophy (GA) that expresses a fusion protein designed to inhibit the activity of complement C3 and C5, with the objective of slowing GA lesion growth and vision loss
  • Kriya Announces Thirteen Presentations at the American Society of Gene . . .
    Kriya is a biopharmaceutical company developing gene therapies to address chronic diseases affecting millions of people around the world With operations in Research Triangle Park, North Carolina, and Palo Alto, California, Kriya has raised over $600 million to advance a broad pipeline of gene therapies in ophthalmology, metabolic disease and
  • Kriya Announces $150 Million Addition to its Series C, Bringing Total . . .
    With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $600 million in committed capital, which will be used to advance a broad pipeline of gene therapies for ophthalmology, neurology and metabolic disease
  • Opthalmology: Gene Therapy for Geographic Atrophy - Kriya Therapeutics
    Kriya’s AAV gene therapy encodes an antibody that blocks Insulin-like Growth Factor 1 (IGF1) receptors By blocking IGF1 receptors, this antibody decreases pro-inflammatory Thyrotropin Receptor (TSHR) autoantibody signaling, which may lead to reductions in proptosis and diplopia
  • Our Team: Leaders in Gene Therapy - Kriya Therapeutics
    Andrew Murphy is the Sr Vice President, Early Research at Kriya Therapeutics Dr Murphy joined Kriya from Kitty Hawk Biosciences where he developed in vitro assays to support client gene therapy programs He has over fifteen years of experience in biopharmaceutical research and development from discovery to early clinical evaluation





中文字典-英文字典  2005-2009